Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T19:12:34.634Z.
Calculation as of: 2026-10-06T19:12:34.634Z.
Quote observation: 2026-10-06T18:54:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0dc40ddd6b0c815ea8fb06d6c0f10798674f4babd9a38c246e46e89e51900236
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$48.76M
PS Ratio
140.93
TTM Avg
825.85
3Y Avg
825.85
5Y Avg
825.85
Market Cap
$49.47M
PS Ratio
1.57
TTM Avg
1.42
3Y Avg
1.62
5Y Avg
1.97
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lite Strategy, Inc. (LITS) | $47.81M | N/A | N/A | N/A | N/A |
| Instil Bio, Inc. (TIL)vs › | $47.41M | N/A | 32485.46 | 32485.46 | 32485.46 |
| Apollomics, Inc. (APLM)vs › | $49.02M | N/A | N/A | N/A | N/A |
| Sensus Healthcare, Inc. (SRTS)vs › | $49.06M | 2.80 | 2.20 | 2.26 | 2.94 |
| TELA Bio, Inc. (TELA)vs › | $49.44M | 0.62 | 0.61 | 1.28 | 2.70 |
| Celularity Inc. (CELU)vs › | $46.31M | 2.44 | 0.93 | 1.92 | 8.84 |
| Microbot Medical Inc. (MBOT)vs › | $48.76M | 140.93 | 825.85 | 825.85 | 825.85 |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.47M | 1.57 | 1.42 | 1.62 | 1.97 |
| INmune Bio, Inc. (INMB)vs › | $49.58M | N/A | 1293.91 | 1758.59 | 3330.34 |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $50.16M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q2 FY2026Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q3 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q4 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-30 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
